

Cape Verde


Phase: Pre-elimination. Coverage: In 2010, IRS was sufficient to protect >50% of the population at risk.

I. EPIDEMIOLOGICAL PROFILE

| Population (UN Population Division) | 2010 | % |
|--|---------|----|
| High transmission (≥ 1 case per 1000 population) | 0 | 0 |
| Low transmission (0-1 cases per 1000 population) | 129 000 | 26 |
| Malaria-free (0 cases) | 367 000 | 74 |
| Total | 496 000 | |

Parasites and vectors

Major plasmodium species: *P. falciparum* (100%), *P. vivax*
 Major anopheles species: *An. gambiae*, *arabiensis*



II. INTERVENTION POLICIES AND STRATEGIES


| Intervention | WHO-recommended policies/strategies | Yes/No | Year adopted |
|-----------------|---|--------|--------------|
| ITN | ITNs/ LLINs: distributed free of charge | No | - |
| | ITNs/ LLINs: distributed to all age groups | No | - |
| IRS | IRS is recommended | Yes | 1998 |
| | DDT is used for IRS | No | - |
| IPT | IPT used to prevent malaria during pregnancy | No | - |
| Case management | Patients of all ages should receive diagnostic test | Yes | 1998 |
| | RDTs used at community level | Yes | 2008 |
| | ACT is free for all ages in public sector | Yes | 2008 |
| | Pre-referral treatment with recommended medicines | Yes | - |
| | Oral artemisinin-based monotherapies are not registered | No | - |

| Antimalarial policy | Medicine | Year adopted |
|--|----------|--------------|
| First-line treatment of unconfirmed malaria | AL | 2007 |
| First-line treatment of <i>P. falciparum</i> | AL | 2007 |
| Treatment failure of <i>P. falciparum</i> | QN | - |
| Treatment of severe malaria | QN | - |
| Treatment of <i>P. vivax</i> | - | - |


Therapeutic efficacy tests (therapeutic or parasitological failure, %)

| Medicine | Year | No. of Studies | Min | Median | Max | Follow-up |
|----------|------|----------------|-----|--------|-----|-----------|
|----------|------|----------------|-----|--------|-----|-----------|


III. FINANCING – Government and external financing




Expenditure by intervention in 2010




IV. COVERAGE – Coverage of ITN and IRS



Cases tested and ACT delivered: Programme data (public sector)



V. IMPACT – Malaria test positivity rate and ABER



Confirmed cases, admissions and deaths (per 100 000)

